Paradigm Biocapital Advisors’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Paradigm Biocapital Advisors’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,175,879	Closed	-$80.1M	–	32
2022 Q3	$80.1M	Sell	1,175,879 -269,687	-19%	-$14.9M	10.68%	1
2022 Q2	$46.2M	Buy	1,445,566 +478,739	+50%	+$14M	9.21%	2
2022 Q1	$33.5M	Buy	966,827 +186,347	+24%	+$5.57M	8.86%	2
2021 Q4	$22.8M	Buy	+780,480	New	+$24.2M	6.52%	6

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Paradigm Biocapital Advisors's GBT Position: Q4 2022 in Review

Paradigm Biocapital Advisors sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 1,175,879 shares — an estimated $80.1M sold.

Paradigm Biocapital Advisors first reported a position in GBT in Q4 2021 and held it in 4 quarters. The position peaked at $80.1M in Q3 2022. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Paradigm Biocapital Advisors reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Paradigm Biocapital Advisors sold 1,175,879 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $80.1M.
Paradigm Biocapital Advisors first reported a position in Global Blood Therapeutics, Inc. in Q4 2021 and held it in 4 quarters.
Paradigm Biocapital Advisors's Global Blood Therapeutics, Inc. position peaked at $80.1M in Q3 2022.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.